NEUROMARK Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
70
- Latest Deal Type
-
Debt
- Latest Deal Amount
-
$29M
- Investors
-
11
NEUROMARK General Information
Description
Developer of a non-surgical intervention device designed to treat chronic rhinitis safely. The company specializes in minimally invasive hand-held radio-frequency devices that are introduced through the nostrils into the nasal cavity under direct endoscopic visualization where it deploys a microelectrode array that delivers targeted energy to interrupt the autonomic function within the mucosal structures of nasal cavities which will reverse the inflammatory cascade, enabling surgeons to treat patients in an office setting, removing the complications and costs associated with most surgical procedures.
Contact Information
Website
www.neuromark.comCorporate Office
- 150 Grossman Drive
- Suite 203
- Braintree, MA 02184
- United States
Corporate Office
- 150 Grossman Drive
- Suite 203
- Braintree, MA 02184
- United States
NEUROMARK Timeline
NEUROMARK Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Debt - General | 09-Sep-2026 | $29M | Completed | Generating Revenue | ||
| 9. Later Stage VC (Series C) | 17-Feb-2026 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 18-Dec-2024 | Completed | Generating Revenue | |||
| 7. Later Stage VC | 07-Jun-2022 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | 30-May-2021 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series B) | 20-Jan-2021 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B) | 07-May-2020 | Completed | Generating Revenue | |||
| 3. Grant | 10-Dec-2018 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 16-Jul-2018 | $10.8M | $10.8M | Completed | Generating Revenue | |
| 1. University Spin-Out | 01-Jan-2014 | Completed | Generating Revenue |
NEUROMARK Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A Preference | ||||||||
| Series A Preference | 123,547 | $0.001089 | $40.96 | $40.96 | 1x | $40.96 | 22.75% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
NEUROMARK Comparisons
Industry
Financing
Details
NEUROMARK Competitors (8)
One of NEUROMARK’s 8 competitors is Spine Wave, a Venture Capital-Backed company based in Shelton, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Spine Wave | Venture Capital-Backed | Shelton, CT | ||||
| Naväge | Private Equity-Backed | Brooklyn, OH | ||||
| Amplitude Surgical | Formerly PE-Backed | Valence, France | ||||
| Boston Scientific | Corporation | Marlborough, MA | ||||
| Merit Medical Systems | Corporation | South Jordan, UT |
NEUROMARK Patents
NEUROMARK Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4773900-A1 | Systems and methods for treating headache disorders | Pending | 05-Sep-2023 | ||
| US-20250072955-A1 | Systems and methods for treating headache disorders | Pending | 05-Sep-2023 | ||
| WO-2025052173-A1 | Systems and methods for treating headache disorders | Inactive | 05-Sep-2023 | ||
| EP-4770551-A1 | Device for therapeutic sino-nasal treatment | Pending | 28-Aug-2023 | ||
| US-20250072951-A1 | Device for therapeutic sino-nasal treatment | Pending | 28-Aug-2023 | A61B18/14 |
NEUROMARK Signals
NEUROMARK Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| MVM Partners | Growth/Expansion | Minority | ||
| Sofinnova Partners | Venture Capital | Minority | ||
| Claret Capital Partners | Growth/Expansion | Minority | ||
| MedTech Innovator | Accelerator/Incubator | Minority | ||
| EQT Life Sciences | Venture Capital | Minority |
NEUROMARK FAQs
-
When was NEUROMARK founded?
NEUROMARK was founded in 2014.
-
Where is NEUROMARK headquartered?
NEUROMARK is headquartered in Braintree, MA.
-
What is the size of NEUROMARK?
NEUROMARK has 70 total employees.
-
What industry is NEUROMARK in?
NEUROMARK’s primary industry is Therapeutic Devices.
-
Is NEUROMARK a private or public company?
NEUROMARK is a Private company.
-
What is NEUROMARK’s current revenue?
The current revenue for NEUROMARK is .
-
How much funding has NEUROMARK raised over time?
NEUROMARK has raised $176M.
-
Who are NEUROMARK’s investors?
MVM Partners, Sofinnova Partners, Claret Capital Partners, MedTech Innovator, and EQT Life Sciences are 5 of 11 investors who have invested in NEUROMARK.
-
Who are NEUROMARK’s competitors?
Spine Wave, Naväge, Amplitude Surgical, Boston Scientific, and Merit Medical Systems are some of the 8 competitors of NEUROMARK.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process